1. Clinical & Scientific Overview
Ifosfamide (TIP-MED-000550, Reference Code [ONC-01]) is classified under
Oncology & Antineoplastic Medicines as a Alkylating Agent (Prodrug) • Oxazaphosphorine Nitrogen Mustard Alkylating Agent.
Within the Indian regulatory and compendial framework, it is governed under Schedule H (Prescription Only — Specialist Oncology Supervision).
Holoxan (Baxter / Zydus Oncology), Ifex Reference, Ipamide (Fresenius Kabi Oncology)
Lyophilised Powder for IV Infusion: 1 g vial, 2 g vial
Oncology Specialisation & Cytotoxic Safety Protocol
Alkylating Agent (Prodrug)
Antineoplastic Cytotoxic
Standard Regimen & Cycle Context: Sarcoma / Lymphoma fractionated regimen: 1.2–2.5 g/m2/day IV over 1–4 hours on Days 1–3 or 1–5 of a 21-day cycle, ALWAYS co-administered with Mesna.
Signature Dose-Limiting Toxicities & Organ Monitoring: Haemorrhagic cystitis (prevented by Mesna + 2–3 L/day IV hydration), Dose-limiting Encephalopathy/Neurotoxicity (10–30% — caused by chloroacetaldehyde crossing the blood-brain barrier; treated/prevented with IV Methylene Blue 50 mg q4–8h and thiamine), Fanconi-like proximal renal tubular acidosis, and severe myelosuppression.
Extravasation, Premedication & Safe Cytotoxic Handling: Mandatory co-administration of Mesna (at 20% w/w of ifosfamide dose at 0, 4, and 8 hours or continuous 1:1 infusion) and vigorous hydration; monitor urine dipstick for microscopic haematuria before each dose and assess mental status for confusion/cerebellar ataxia.
3. Mechanism of Action & Pharmacodynamics
Hepatic CYP3A4 and CYP2B6 hydroxylate ifosfamide into 4-hydroxyifosfamide and aldoifosfamide, which spontaneously cleave into phosphoramide mustard (cross-links DNA N7-guanine strands) and acrolein (urotoxic metabolite).
4. Therapeutic Indications & Evidence-Supported Uses
- Germ cell testicular tumours
- Soft tissue and osteogenic sarcomas (ICE / AIM regimens)
- Relapsed non-Hodgkin and Hodgkin lymphoma
🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.
5. Educational Dosage Context, Formulations & Administration
Educational Dosing & Regimen Summary: Educational Oncology Regimen Context (Specialist Reference Only): Sarcoma / Lymphoma fractionated regimen: 1.2–2.5 g/m2/day IV over 1–4 hours on Days 1–3 or 1–5 of a 21-day cycle, ALWAYS co-administered with Mesna.
Administration & Meal Timing: Sarcoma / Lymphoma fractionated regimen: 1.2–2.5 g/m2/day IV over 1–4 hours on Days 1–3 or 1–5 of a 21-day cycle, ALWAYS co-administered with Mesna.
6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment
Specialist oncology pharmacokinetic profile; dosing depends on Body Surface Area (BSA in m2), Calvert GFR formula, or flat targeted dosing with strict organ-function adjustments.
Hepatic enzymatic activation/inactivation or proteolytic degradation (for monoclonal antibodies); see specific polymorphism and interaction notes.
Verify serum creatinine and eGFR before every cycle; see drug-specific renal dosing and uroprotection rules.
Check total bilirubin, AST, and ALT prior to each cycle; taxanes, anthracyclines, and TKIs require strict hepatic dose modification.
7. Contraindications, Precautions & High-Risk Warnings
- Severe hypersensitivity to Ifosfamide or formulation vehicle
- Pregnancy and lactation (potent teratogen/embryotoxic class warning unless explicitly evaluated by oncology specialist)
- Severe unrecovered bone marrow aplasia or decompensated organ failure per protocol thresholds
Key Clinical Precautions: Haemorrhagic cystitis (prevented by Mesna + 2–3 L/day IV hydration), Dose-limiting Encephalopathy/Neurotoxicity (10–30% — caused by chloroacetaldehyde crossing the blood-brain barrier; treated/prevented with IV Methylene Blue 50 mg q4–8h and thiamine), Fanconi-like proximal renal tubular acidosis, and severe myelosuppression.
8. Adverse Effects Profile
- Haemorrhagic cystitis (prevented by Mesna + 2–3 L/day IV hydration), Dose-limiting Encephalopathy/Neurotoxicity (10–30% — caused by chloroacetaldehyde crossing the blood-brain barrier; treated/prevented with IV Methylene Blue 50 mg q4–8h and thiamine), Fanconi-like proximal renal tubular acidosis, and severe myelosuppression.
- Haemorrhagic cystitis (prevented by Mesna + 2–3 L/day IV hydration), Dose-limiting Encephalopathy/Neurotoxicity (10–30% — caused by chloroacetaldehyde crossing the blood-brain barrier; treated/prevented with IV Methylene Blue 50 mg q4–8h and thiamine), Fanconi-like proximal renal tubular acidosis, and severe myelosuppression.
9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions
- Haemorrhagic cystitis (prevented by Mesna + 2–3 L/day IV hydration), Dose-limiting Encephalopathy/Neurotoxicity (10–30% — caused by chloroacetaldehyde crossing the blood-brain barrier; treated/prevented with IV Methylene Blue 50 mg q4–8h and thiamine), Fanconi-like proximal renal tubular acidosis, and severe myelosuppression.
- Avoid live-attenuated vaccines during immunosuppressive chemotherapy; verify CYP3A4, UGT1A1, DPD, and QTc interactions before each cycle.
10. Clinical Monitoring, Patient Counselling & Storage
Clinical & Laboratory Monitoring: Mandatory co-administration of Mesna (at 20% w/w of ifosfamide dose at 0, 4, and 8 hours or continuous 1:1 infusion) and vigorous hydration; monitor urine dipstick for microscopic haematuria before each dose and assess mental status for confusion/cerebellar ataxia.
Pharmacist Patient Counselling Points:
- Mandatory co-administration of Mesna (at 20% w/w of ifosfamide dose at 0, 4, and 8 hours or continuous 1:1 infusion) and vigorous hydration; monitor urine dipstick for microscopic haematuria before each dose and assess mental status for confusion/cerebellar ataxia.
- Report fever >=38.0°C (100.4°F) immediately (medical emergency: possible febrile neutropenia).
- Follow strict reproductive contraception and safe cytotoxic oral handling instructions.
Storage, Stability & Dispensing Safeguards: Mandatory co-administration of Mesna (at 20% w/w of ifosfamide dose at 0, 4, and 8 hours or continuous 1:1 infusion) and vigorous hydration; monitor urine dipstick for microscopic haematuria before each dose and assess mental status for confusion/cerebellar ataxia.
11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)
12. Authoritative References, Regulatory Sources & Editorial Disclaimer
Primary Compendial & Guideline Reference: National Cancer Grid (NCG) India Consensus Guidelines; NLEM 2022 Antineoplastic Section; Indian Pharmacopoeia (IP) & CDSCO Approved Oncology Prescribing Information.
Official Verification Portals: National Cancer Grid (NCG) India — Evidence-Based Oncology Guidelines • CDSCO — Central Drugs Standard Control Organization Approved Drug Data • Indian Pharmacopoeia Commission (IPC)
Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: VERIFIED_EDUCATIONAL_CONTENT
Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.
13. Related Reference Monographs, Educational Guides & Visual Concept
💊 Related Pharmacological / Category Profiles
- [ONC-30] Mesna (Sodium 2-Mercaptoethanesulfonate) — Oncology Supportive Care (Uroprotector) • Sulfhydryl Uroprotectiv
- [ONC-02] Melphalan — Alkylating Agent • Phenylalanine Nitrogen Mustard Bifunctional Al
- [ONC-03] Temozolomide — Alkylating / Methylating Agent • Imidazotetrazine Oral DNA Methyl
- [ONC-04] Cytarabine (Ara-C) — Antimetabolite (S-Phase Specific) • Pyrimidine Nucleoside Analogu
